BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pan X, Zhou Z, Jin X, Shi D. Clinical characteristics and risk factors of severe hyponatremia in cirrhotic patients treated with terlipressin. J Clin Pharm Ther 2020;45:191-8. [DOI: 10.1111/jcpt.13057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Qi X, Bai Z, Zhu Q, Cheng G, Chen Y, Dang X, Ding H, Han J, Han L, He Y, Ji F, Jin H, Li B, Li H, Li Y, Li Z, Liu B, Liu F, Liu L, Lin S, Ma D, Meng F, Qi R, Ren T, Shao L, Tang S, Tang Y, Teng Y, Wang C, Wang R, Wu Y, Xu X, Yang L, Yuan J, Yuan S, Yang Y, Zhao Q, Zhang W, Yang Y, Guo X, Xie W. Practice guidance for the use of terlipressin for liver cirrhosis–related complications. Therap Adv Gastroenterol 2022;15:175628482210982. [DOI: 10.1177/17562848221098253] [Reference Citation Analysis]
2 Kulkarni AV, Arab JP, Premkumar M, Benítez C, Tirumalige Ravikumar S, Kumar P, Sharma M, Reddy DN, Simonetto DA, Rao PN. Terlipressin has stood the test of time: Clinical overview in 2020 and future perspectives. Liver Int 2020;40:2888-905. [DOI: 10.1111/liv.14703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]